Allon granted US patent for composition of matter

14-Jun-2007

Allon Therapeutics Inc. announced that it has been granted a US patent covering additional composition of matter for the products in the ADNP platform, which broadens the intellectual property of Allon's patent portfolio. Gordon McCauley, President and CEO of Allon, said these claims provide further independent validation of the unique and important nature of these highly novel neuroprotective peptides.

The allowed claims relate to the nucleic acid composition of Allon's drug candidates AL-108 and AL-208, which are both currently being evaluated in Phase II human efficacy trials. The Company has three Phase II clinical efficacy programs. AL-108 is being evaluated in two separate trials, one for Alzheimer's disease and another for schizophrenia related cognitive impairment. AL-208 is being evaluated as a treatment for the mild cognitive impairment associated with coronary artery bypass graft (MCI-CABG) surgery.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances